Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01212692
Other study ID # NA_00039100
Secondary ID R01AG034934
Status Completed
Phase Phase 2
First received September 30, 2010
Last updated December 8, 2015
Start date October 2010
Est. completion date June 2014

Study information

Verified date December 2015
Source Johns Hopkins University
Contact n/a
Is FDA regulated No
Health authority United States: Federal GovernmentUnited States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to learn if activities that challenge the brain (mentally stimulating activities) can improve memory and other types of thinking in patients with Mild Cognitive Impairment. The study will compare the effects of different methods of mental stimulation.


Recruitment information / eligibility

Status Completed
Enrollment 63
Est. completion date June 2014
Est. primary completion date June 2014
Accepts healthy volunteers No
Gender Both
Age group 50 Years to 100 Years
Eligibility Inclusion Criteria:

- = 50 years of age

- meet criteria for amnestic-Mild Cognitive Impairment (MCI)

- have capacity to give informed consent

- have capacity to complete assessment measures

Exclusion Criteria:

- history of drug or alcohol dependence

- severe psychiatric conditions associated with psychosis (e.g., schizophrenia)

- recent stroke

- clinical diagnosis of probable Alzheimer's Disease

- history of seizure disorder, serious head trauma, or other medical, psychiatric, or neurological conditions associated with significant cognitive impairment (e.g., Parkinson's Disease, Korsakoff's, HIV)

- current use of Alzheimer's Disease medications (e.g., cholinesterase inhibitors, memantine)

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment


Intervention

Behavioral:
mentally stimulating activities
The study will compare the effects of different methods of mental stimulation. The intervention involves 6 classroom-style educational sessions and 10 mental stimulation studies involving computerized memory tasks.

Locations

Country Name City State
United States BPRU, Johns Hopkins Bayview Medical Center Baltimore Maryland

Sponsors (2)

Lead Sponsor Collaborator
Johns Hopkins University National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Self-Ordered Pointing Task baseline No
Primary Trail-Making baseline No
Primary Timed Instrumental Activities of Daily Living baseline No
Primary Rey Auditory Verbal Learning Test baseline No
Primary Self-ordered pointing task immediately after the intervention No
Primary Self-ordered pointing task 3 months post intervention No
Primary Self-ordered pointing task 9 months post-intervention No
Primary Trail-Making immediately after the intervention No
Primary Trail-Making 3 months post-intervention No
Primary Trail-Making 9 months post-intervention No
Primary Timed Instrumental Activities of Daily Living immediately after the intervention No
Primary Timed Instrumental Activities of Daily Living 3 months post-intervention No
Primary Timed Instrumental Activities of Daily Living 9 months post-intervention No
Primary Rey Auditory Verbal Learning Test immediately after the intevention No
Primary Rey Auditory Verbal Learning Test 3 months post-intervention No
Primary Rey Auditory Verbal Learning Test 9 months post-intervention No
Secondary Clinical Dementia Rating Scale baseline, immediately after the intervention, 3 months post intervention, and 9 months post-intervention No
Secondary Digit Symbol Substitution Test baseline, immediately after the intervention, 3 months post intervention, and 9 months post-intervention No
Secondary Digit Span baseline, immediately after the intervention, 3 months post intervention, and 9 months post-intervention No
Secondary Verbal Fluency Test baseline, immediately after the intervention, 3 months post intervention, and 9 months post-intervention No
Secondary Geriatric Depression Scale baseline, immediately after the intervention, 3 months post intervention, and 9 months post-intervention No
Secondary Neuropsychiatric Inventory baseline, immediately after the intervention, 3 months post intervention, and 9 months post-intervention No
Secondary Recollection Task baseline, immediately after the intervention, 3 months post intervention, and 9 months post-intervention No
Secondary N-Back baseline, immediately after the intervention, 3 months post intervention, and 9 months post-intervention No
Secondary Rivermead Behavioral Memory Test baseline, immediately after the intervention, 3 months post intervention, and 9 months post-intervention No
Secondary Instrumental Activities of Daily Living baseline, immediately after the intervention, 3 months post intervention, and 9 months post-intervention No
Secondary Functional Capacities for Activities of Daily Living baseline, immediately after the intervention, 3 months post intervention, and 9 months post-intervention No
Secondary Multifactorial Memory Questionnaire baseline, immediately after the intervention, 3 months post intervention, and 9 months post-intervention No
See also
  Status Clinical Trial Phase
Completed NCT00934531 - Donepezil and the Risk of Falls in Seniors With Cognitive Impairment N/A
Withdrawn NCT05033912 - A Study of CST-2032 in Subjects With Cognitive Impairment Phase 1
Recruiting NCT02854033 - Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
Completed NCT01902004 - Brain Aging and Treatment Response in Geriatric Depression Phase 4
Recruiting NCT00544791 - The Effect of Melatonin on Cognitive Function in Patients Diagnosed With Mild Cognitive Impairment Phase 2
Withdrawn NCT04055532 - Biomarkers in Neurodegenerative Diseases
Terminated NCT02180529 - The Effects of Methylphenidate on the Cognitive Function of Older People With Mild Cognitive Impairment N/A
Completed NCT05108922 - A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4) Phase 3
Recruiting NCT05865340 - To Exam the Efficacy of Oral Health and Mediterranean Diet Interventions in Preventing Cognitive Decline Among Older Adults With Mild Cognitive Impairment N/A
Completed NCT06417034 - Hand Training Device For Cognitive Care N/A
Completed NCT02110043 - Modulation of Visual-Spatial Learning in Patients With Mild Cognitive Impairment (MCI) by tDCS N/A
Completed NCT01383161 - 18-Month Study of Memory Effects of Curcumin Phase 2
Completed NCT01299766 - Preventing Cognitive Decline in African Americans With Mild Cognitive Impairment Phase 3
Withdrawn NCT05321498 - Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation Phase 2
Completed NCT04748666 - PST for Care Partners of Adults With Alzheimer's and Alzheimer'S-related Dementia N/A
Recruiting NCT03138018 - Aging Stereotypes and Prodromal Alzheimer's Disease N/A
Withdrawn NCT01891383 - Clinical Characteristics of Dementias That Occur Remotely After Traumatic Brain Injury in Retired Military Personnel
Recruiting NCT03448055 - Nutritional Intervention With the Dietary Supplement, Immunocal® in MCI Patients: Promotion of Brain Health N/A
Completed NCT01231971 - Alzheimer's Disease Neuroimaging Initiative 2
Completed NCT01044758 - Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI) Phase 2